Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life. These data will be collected using a special patient questionnaire (Endometriosis Health Profile 5, EHP-5). The study will also be used to describe the basic disease status and demographic characteristics of patients searching treatment by a gynecologist because of their endometriosis. In addition, the study will give insight into the typical diagnostic measures the physicians in different countries are using in the field of endometriosis.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Dienogest

Criteria

Inclusion Criteria:

• Female patients older than 18 years of age

• Clinical or laparoscopic diagnosis of endometriosis

• Having endometriosis related pain as leading symptom

• Decision taken by physician to prescribe Visanne

• Signed Informed Consent Form

Exclusion Criteria:

• Contraindications listed in the local summary of product characteristics (SPC) have to be considered.